The Relationship Between HER-2 Expression Levels and 18F-FDG PET/CT Parameters in Gastric Cancer
Yıl: 2021 Cilt: 30 Sayı: 3 Sayfa Aralığı: 32 - 39 Metin Dili: İngilizce DOI: 10.4274/mirt.galenos.2021.78055 İndeks Tarihi: 03-02-2022
The Relationship Between HER-2 Expression Levels and 18F-FDG PET/CT Parameters in Gastric Cancer
Öz: Objectives: Human epidermal growth factor receptor-2 (HER-2) is a protooncogene encoded by ERBB2 on chromosome 17. 18Fluoridefluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) examination is frequently used to detect distant metastasis in gastric cancer imaging. This study aimed to investigate the relationship between the data obtained in the 18F-FDG PET/CT examination and HER-2 expression status in patients with gastric cancer. Methods: A total of 115 patients diagnosed with gastric cancer between 2016 and 2020, with HER-2 immunohistochemical followed by 18F-FDG PET/CT examination for staging purposes were included. Results: HER-2 immunohistochemical examination revealed 71 patients (61.7%) with negative and 44 (38.3%) with positive results. The median maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) values of patients positive with HER-2 were 9.95, 5, 30.44, and 139.16, respectively, whereas patients negative with HER-2 were 9.3,5.4,36.62, and 190.424, respectively (p>0.05). The median cancer antigen 19-9 (CA 19-9) levels of patients positive with HER-2 was 33.52, whereas 11.79 in those who were negative (p=0.016). The mean age was 69.3±9.35 years in patients with distant metastases, whereas 65.2±10.9 in those without distant metastases (p=0.042). Median SUVmax and SUVmean values in patients with distant metastases were 11.1 and 6.3, respectively, and 8.2 and 4.5 in those without distant metastases (p=0.002 and p=0.001, respectively). The median CA 19-9 and carcinoembryonic antigen (CEA) levels in patients with distant metastases were 31.34 and 9.20, respectively, whereas those without distant metastases were 11.55 and 2.26, respectively (p=0.011 and p=0.001, respectively). Conclusion: In our study, no statistically significant difference was found in terms of HER-2 status, SUVmax, SUVmean, MTV, TLG, distant metastasis, presence of lymph node metastasis, age, gender, tumor diameter, grade, and localization, and CEA levels in patients with gastric cancer. A statistically significant difference was found between HER-2 status and CA 19-9 levels. A statistically significant relationship was found between distant metastases in the 18F-FDG PET/CT examination and SUVmax, SUVmean, age, CEA levels, and histopathologic diagnosis; however, the relationship between distant metastasis in the 18F-FDG PET/CT scan and MTV, TLG, tumor diameter, localization, and grade was not statistically significant.
Anahtar Kelime: Mide Kanseri Hastalarında HER-2 Ekspresyon Düzeyleri ve 18F-FDG PET/BT Parametreleri Arasındaki İlişki
Öz: Amaç: İnsan epidermal büyüme faktörü reseptörü-2 (HER-2) kromozom 17 üzerinde ERBB2 tarafından kodlanan bir protoonkogendir. Mide kanseri görüntülemesinde 18fluoride-florodeoksiglikoz pozitron emisyon tomografi/bilgisayarlı tomografi (18F-FDG PET/BT) tetkiki uzak metastaz taraması için sıklıkla kullanılmaktadır. Bizim bu çalışmadaki amacımız patolojik olarak mide kanseri tanısı konmuş hastalarda 18F-FDG PET/BT tetkikinde elde edilen veriler ile HER-2 ekspresyonu arasındaki ilişkinin araştırılmasıdır. Yöntem: Çalışmamıza 2016 ve 2020 yılları arasında mide kanseri tanısı konulmuş, evreleme amacıyla 18F-FDG PET/BT tetkiki yapılmış ve patolojik olarak HER-2 incelemesi yapılmış 115 mide kanseri hastası dahil edilmiştir. Bulgular: Çalışmamızdaki hastaların HER-2 immünohistokimyasal incelemesine göre 71’i (%61,7) negatif, 44’ü (%38,3) pozitif olarak değerlendirilmiştir. HER-2 pozitif olan hastaların medyan maksimum standartlaştırılmış alım değeri (SUVmaks), ortalama standartlaştırılmış alım değeri (SUVortalama), metabolik tümör hacmi (MTV), toplam lezyon glikoliz (TLG) değeri sırasıyla 9,95, 5, 30,44, 139,16 iken, HER-2 negatif olan hastaların ise sırasıyla 9,3, 5,4, 36,62 ve 190,424 idi (p>0,05). HER-2 pozitif olan hastaların medyan CA 19-9 değeri 33,52 iken, negatif olan hastaların 11,79 idi (p=0,016). 18F-FDG PET/BT tetkikinde uzak metastaz bulunan hastalarda ortalama yaş 69,3±9,35 iken, uzak metastaz olmayanlarda ortalama yaş 65,2±10,9 idi (p=0,042). 18F-FDG PET/BT tetkikinde uzak metastaz bulunan hastalarda medyan SUVmaks ve SUVortalama değerleri sırasıyla 11,1 ve 6,3 iken, uzak metastaz olmayanlarda sırasıyla 8,2 ve 4,5 idi (p=0,002, p=0,001 sırasıyla). Uzak metastaz bulunan hastalarda medyan CA 19-9 ve CEA düzeyleri sırasıyla 31,34 ve 9,20 iken, uzak metastaz olmayanlarda sırasıyla 11,55 ve 2,26 idi (p=0,011 ve p=0,001 sırasıyla). Sonuç: Çalışmamızda mide kanseri hastalarında HER-2 durumu ile SUVmaks, SUVortalama, MTV, TLG, uzak metastaz varlığı, lenf nodu metastazı varlığı, yaş, cinsiyet, tümör çapı, tümör derecesi, tümör lokalizasyonu ve CEA düzeyleri açısından istatistiksel olarak anlamlı bir farklılık yoktu ancak HER-2 durumu ile CA 19-9 değerleri arasında istatistiksel olarak anlamlı bir fark bulundu. 18F-FDG PET/BT tetkikinde uzak metastaz bulunması ile SUVmaks, SUVortalama, yaş, CEA düzeyleri ve histopatolojik tanı arasında istatistiksel olarak anlamlı bir ilişki saptanırken, MTV, TLG, tümör çapı, tümör lokalizasyonu ve tümör derecesi arasındaki ilişki istatistiksel olarak anlamlı değildi.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
- 2. Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 1993;55:891-903.
- 3. Parkin DM. Epidemiology of cancer: global patterns and trends. Toxicol Lett 1998;102-103:227-34.
- 4. Digklia A, Wagner AD. Advanced gastric cancer: Current treatment landscape and future perspectives. World J Gastroenterol 2016;22:2403- 2414.
- 5. Boku N. HER2-positive gastric cancer. Gastric Cancer 2014;17:1-12.
- 6. Meric-Bernstam F, Johnson AM, Dumbrava EEI, Raghav K, Balaji K, Bhatt M, Murthy RK, Rodon J, Piha-Paul SA. Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer. Clin Cancer Res 2019;25:2033-2041.
- 7. Nicole McMillian N, Lenora Pluchino MA, Ajani JA, D TA, Chair V, Bentrem DJ, et al. Gastric Cancer Continue NCCN Guidelines Panel Disclosures. 2019.
- 8. Fox JJ, Autran-Blanc E, Morris MJ, Gavane S, Nehmeh S, Van Nuffel A, Gönen M, Schöder H, Humm JL, Scher HI, Larson SM. Practical approach for comparative analysis of multilesion molecular imaging using a semiautomated program for PET/CT. J Nucl Med 2011;52:1727-1732.
- 9. Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB 3rd, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Am J Clin Pathol 2016;146:647- 669.
- 10. Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel T. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52:797- 805.
- 11. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF; American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med 2014;138:241-256.
- 12. Park JS, Lee N, Beom SH, Kim HS, Lee CK, Rha SY, Chung HC, Yun M, Cho A, Jung M. The prognostic value of volume-based parameters using 18F-FDG PET/CT in gastric cancer according to HER2 status. Gastric Cancer 2018;21:213-224.
- 13. Kim JS, Young Park S. (18)F-FDG PET/CT of advanced gastric carcinoma and association of HER2 expression with standardized uptake value. Asia Ocean J Nucl Med Biol 2014;2:12-18.
- 14. Celli R, Colunga M, Patel N, Djekidel M, Jain D. Metabolic Signature on 18F-FDG PET/CT, HER2 Status, and Survival in Gastric Adenocarcinomas. J Nucl Med Technol 2016;44:234-238.
- 15. Chen R, Zhou X, Liu J, Huang G. Relationship Between 18F-FDG PET/ CT Findings and HER2 Expression in Gastric Cancer. J Nucl Med 2016;57:1040-1044.
- 16. Bai L, Guo CH, Zhao Y, Gao JG, Li M, Shen C, Guo YM, Duan XY. SUVmax of 18F-FDG PET/CT correlates to expression of major chemotherapy-related tumor markers and serum tumor markers in gastric adenocarcinoma patients. Oncol Rep 2017;37:3433-3440.
- 17. Zhou H, Dong A, Xia H, He G, Cui J. Associations between CA19-9 and CA125 levels and human epidermal growth factor receptor 2 overexpression in patients with gastric cancer. Oncol Lett 2018;16:1079- 1086.
| APA | Ertürk S, HASBEK Z, ÖZER H (2021). The Relationship Between HER-2 Expression Levels and 18F-FDG PET/CT Parameters in Gastric Cancer. , 32 - 39. 10.4274/mirt.galenos.2021.78055 |
| Chicago | Ertürk Seyit Ahmet,HASBEK Zekiye,ÖZER Hatice The Relationship Between HER-2 Expression Levels and 18F-FDG PET/CT Parameters in Gastric Cancer. (2021): 32 - 39. 10.4274/mirt.galenos.2021.78055 |
| MLA | Ertürk Seyit Ahmet,HASBEK Zekiye,ÖZER Hatice The Relationship Between HER-2 Expression Levels and 18F-FDG PET/CT Parameters in Gastric Cancer. , 2021, ss.32 - 39. 10.4274/mirt.galenos.2021.78055 |
| AMA | Ertürk S,HASBEK Z,ÖZER H The Relationship Between HER-2 Expression Levels and 18F-FDG PET/CT Parameters in Gastric Cancer. . 2021; 32 - 39. 10.4274/mirt.galenos.2021.78055 |
| Vancouver | Ertürk S,HASBEK Z,ÖZER H The Relationship Between HER-2 Expression Levels and 18F-FDG PET/CT Parameters in Gastric Cancer. . 2021; 32 - 39. 10.4274/mirt.galenos.2021.78055 |
| IEEE | Ertürk S,HASBEK Z,ÖZER H "The Relationship Between HER-2 Expression Levels and 18F-FDG PET/CT Parameters in Gastric Cancer." , ss.32 - 39, 2021. 10.4274/mirt.galenos.2021.78055 |
| ISNAD | Ertürk, Seyit Ahmet vd. "The Relationship Between HER-2 Expression Levels and 18F-FDG PET/CT Parameters in Gastric Cancer". (2021), 32-39. https://doi.org/10.4274/mirt.galenos.2021.78055 |
| APA | Ertürk S, HASBEK Z, ÖZER H (2021). The Relationship Between HER-2 Expression Levels and 18F-FDG PET/CT Parameters in Gastric Cancer. Molecular Imaging and Radionuclide Therapy, 30(3), 32 - 39. 10.4274/mirt.galenos.2021.78055 |
| Chicago | Ertürk Seyit Ahmet,HASBEK Zekiye,ÖZER Hatice The Relationship Between HER-2 Expression Levels and 18F-FDG PET/CT Parameters in Gastric Cancer. Molecular Imaging and Radionuclide Therapy 30, no.3 (2021): 32 - 39. 10.4274/mirt.galenos.2021.78055 |
| MLA | Ertürk Seyit Ahmet,HASBEK Zekiye,ÖZER Hatice The Relationship Between HER-2 Expression Levels and 18F-FDG PET/CT Parameters in Gastric Cancer. Molecular Imaging and Radionuclide Therapy, vol.30, no.3, 2021, ss.32 - 39. 10.4274/mirt.galenos.2021.78055 |
| AMA | Ertürk S,HASBEK Z,ÖZER H The Relationship Between HER-2 Expression Levels and 18F-FDG PET/CT Parameters in Gastric Cancer. Molecular Imaging and Radionuclide Therapy. 2021; 30(3): 32 - 39. 10.4274/mirt.galenos.2021.78055 |
| Vancouver | Ertürk S,HASBEK Z,ÖZER H The Relationship Between HER-2 Expression Levels and 18F-FDG PET/CT Parameters in Gastric Cancer. Molecular Imaging and Radionuclide Therapy. 2021; 30(3): 32 - 39. 10.4274/mirt.galenos.2021.78055 |
| IEEE | Ertürk S,HASBEK Z,ÖZER H "The Relationship Between HER-2 Expression Levels and 18F-FDG PET/CT Parameters in Gastric Cancer." Molecular Imaging and Radionuclide Therapy, 30, ss.32 - 39, 2021. 10.4274/mirt.galenos.2021.78055 |
| ISNAD | Ertürk, Seyit Ahmet vd. "The Relationship Between HER-2 Expression Levels and 18F-FDG PET/CT Parameters in Gastric Cancer". Molecular Imaging and Radionuclide Therapy 30/3 (2021), 32-39. https://doi.org/10.4274/mirt.galenos.2021.78055 |
